Jump to content

  • Set Your Location
  • Sign in or Enroll
Set Your LocationCalifornia Pacific Medical Center
  • Sign in or Enroll
    • Open I want to choose my medical group or hospital
    • Clear my location
Change Location
Sutter Health
  • Video Visits
  • Find Doctors
  • Find Locations
  • Treatments & Services
    • Video Visits
    • Find Doctors
    • Find Locations
    • Treatments & Services
    • COVID-19 Resources
    • Pay a Bill
    • Symptom Checker
    • Get Care Today
    • Health & Wellness
    • Classes & Events
    • Research & Clinical Trials
    • For Patients
    • About Sutter Health
    • Giving
    • Volunteering
    • Careers
    • News
    • For Medical Professionals
    • Other Business Services
Close Search
  • Home
  • CPMC
  • Research
  • Cardiovascular Diseases
Content

Dabigatran versus warfarin for atrial fibrillation in real-world clinical practice: a systematic review and meta-analysis.

Description

Romanelli RJ, Nolting L, Dolginsky M, Kym E, Orrico KB., Circ Cardiovasc Qual Outcomes. pii: CIRCOUTCOMES.115.002369. [Epub ahead of print], 2016 Jan 26

Abstract

BACKGROUND: Trial data for the benefits and risks of dabigatran versus warfarin in the treatment of nonvalvular atrial fibrillation are lacking. We sought to review real-world observational evidence for the comparative effectiveness and safety of these agents.

METHODS AND RESULTS: A systematic search of multiple databases was conducted from first available date to March 10, 2015 for longitudinal, observational studies comparing dabigatran with warfarin. Two reviewers evaluated studies for eligibility and extracted hazard ratios for ischemic stroke and gastrointestinal and intracranial bleeding. hazard ratios were pooled using random-effects meta-analysis. Metaregression was performed to assess treatment-effect heterogeneity. We identified 232 unique citations. Seven retrospective cohort studies met study eligibility criteria, with 348 750 patients and a mean follow-up of 2.2 years. In pooled analyses, dabigatran-150 mg was not superior to warfarin in preventing stroke (hazard ratio, 0.92; 95% confidence interval, 0.84-1.01; P=0.066), but had a significantly lower hazard of intracranial bleeding (0.44; 0.34-0.59; P<0.001). Dabigatran-150 mg had a significantly greater hazard of gastrointestinal bleeding than warfarin (1.23; 1.01-1.50; P=0.041), which was potentiated in studies of older (elderly) versus younger populations (median/mean age, ≥75 versus <75 years; β=1.53; 95% confidence interval, 1.10-2.14; P=0.020).

CONCLUSIONS: In real-world clinical practice, dabigatran is comparable with warfarin in preventing ischemic stroke among patients with nonvalvular atrial fibrillation. However, dabigatran is associated with a lower risk for intracranial bleeding relative to warfarin, but, particularly among the elderly, a greater risk for gastrointestinal bleeding. Bleeding outcomes from observational studies are consistent with those from the pivotal Randomized Evaluation of Long-Term Anticoagulation Therapy trial.

Pubmed Abstract

Pubmed AbstractOpens New Window

Associated Topics

  • Aging and Longevity
  • Cardiovascular Diseases
  • Cerebrovascular Disorders
  • Disease Management
  • Medical Informatics

Related Publications

Patient-initiated electronic messages and quality of care for patients with diabetes and hypertension in a large fee-for-service medical group: results from a natural experiment.

McClellan SR, Panattoni L, Chan AS, Tai-Seale M.
Med Care. [Epub ahead of print]
2016 Jan 12

Precision lifestyle medicine: a new frontier in the science of behavior change and population health.

Ma J, Rosas LG, Lv N.
Am J Prev Med. pii: S0749-3797(15)00638-8. doi: 10.1016/j.amepre.2015.09.035. [Epub ahead of print]
2015 Dec 01

Commentary on Costello JM, et al. Predictions by clinicians of quality of life for children and adolescents with cardiac disease.

Patel M, Wilson SR.
In: Cabana M, ed. Year Book of Pediatrics 2016. Philadelphia, PA: Elsevier; 2015: 199-202. ISBN: 978-0-323-44293-0.
2015 Dec 01

Acceptability and feasibility of the 'DASH for Asthma' intervention in a randomized controlled trial pilot study.

Blonstein AC, Lv N, Camargo CA, Wilson SR, Buist AS, Rosas LG, Strub P, Ma J.
Public Health Nutr. 2015 Dec 10:1-11. [Epub ahead of print]
2015 Dec 10

Health behavior change after blood pressure feedback.

Pu J, Chewning BA, Johnson HM, Vanness DJ, Young HN, Kreling DH.
PLoS One. 10(10):e0141217. doi: 10.1371/journal.pone.0141217. eCollection 2015.
2015 Oct 26
The Sutter Health Network of Care
Expertise to fit your needs
Primary Care

Check-ups, screenings and sick visits for adults and children.

Specialty Care

Expertise and advanced technologies in all areas of medicine.

Emergency Care

For serious accidents, injuries and conditions that require immediate medical care.

Urgent Care

After-hours, weekend and holiday services.

Walk-In Care

Convenient walk-in care clinics for your non-urgent health needs.

  • Contact Us
  • Find Doctors
  • Find Locations
  • Request Medical Records
  • Make a Gift
Sign in to My Health Online

Billing and Insurance

  • Pay a Bill
  • Accepted Health Plans
  • Estimate Costs
  • Medicare Advantage

About Sutter

  • About Our Network
  • Community Benefit
  • Annual Report
  • News

Our Team

  • For Employees
  • For Medical Professionals
  • For Vendors
  • For Volunteers

Careers

  • Jobs at Sutter
  • Physician Jobs
  • Graduate Medical Education

Copyright © 2023 Sutter Health. All rights reserved. Sutter Health is a registered trademark of Sutter Health ®, Reg. U.S. Patent & Trademark office.

  • ADA Accessibility
  • Privacy
  • Do Not Sell My Personal Information
  • LinkedIn Opens new window
  • YouTube Opens new window
  • Facebook Opens new window
  • Twitter Opens new window
  • Instagram Opens new window
  • Glassdoor Opens new window

Cookie Policy

We use cookies to give you the best possible user experience. By continuing to use the site, you agree to the use of cookies. Privacy Policy Cookie Preferences

Privacy Policy Cookie Preferences